BioArctic's Capital Markets Day 2025 - entering a new era of growth
07.08.2025 - 18:03:42Telephone: +46 73 515 09 70
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit?www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/9978/4157690/3480820.pdf
BioArctic’s Capital Markets Day 2025 â€" entering a new era of growth
View original content:https://www.prnewswire.co.uk/news-releases/bioarctics-capital-markets-day-2025--entering-a-new-era-of-growth-302470543.html
